Presbia (LENSF) 10-K 29 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 15, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1,591,096
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,032,691
Entity Public Float			$ 17,180,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash	$ 7,333	$ 21,749
Accounts receivable	3	116
Inventory	302	430
Prepaid expenses and other current assets	392	242
Total current assets	8,030	22,537
Property and equipment, net	727	775
Intangible assets	1,494	32
Other assets	126	63
Total assets	10,377	23,407
Current liabilities
Accounts payable	399	736
Due to related parties	18	55
Note payable, current portion	490
Other current liabilities	582	569
Total current liabilities	1,489	1,360
Note payable, net of current portion	369
Deferred rent	80	22
Total liabilities	1,938	1,382
Commitments and contingencies (note 13)
Shareholders' equity
Ordinary Shares $0.001 par value, 350,000,000 shares authorized; 13,420,927 and 13,335,477 shares issued and outstanding at December 31, 2016 and 2015, respectively	13	13
Deferred Ordinary Shares € 1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at December 31, 2016 and 2015	54	54
Preferred Shares $0.001 par value, 50,000,000 shares authorized; -0- shares issued and outstanding at December 31, 2016 and 2015
Additional paid-in capital	79,676	77,505
Accumulated deficit	(71,304)	(55,547)
Total shareholders' equity	8,439	22,025
Total liabilities and shareholders’ equity	$ 10,377	$ 23,407

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2016$ / sharesshares	Dec. 31, 2016€ / sharesshares	Dec. 31, 2015$ / sharesshares	Dec. 31, 2015€ / sharesshares
Statement Of Financial Position [Abstract]
Ordinary shares, par value | $ / shares	$ 0.001		$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	13,420,927	13,420,927	13,335,477	13,335,477
Ordinary shares, shares outstanding	13,420,927	13,420,927	13,335,477	13,335,477
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1	$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares issued	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares outstanding	39,994	39,994	39,994	39,994
Preferred shares, par value | $ / shares	$ 0.001		$ 0.001
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000	50,000,000
Preferred shares, shares issued	0	0	0	0
Preferred shares, shares outstanding	0	0	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues	$ 14	$ 153
Cost of goods sold	279	163
Gross loss	(265)	(10)
Operating expenses:
Research and development	5,541	7,935
Sales and marketing	3,103	2,706
General and administrative	6,750	7,479
Total operating expenses	15,394	18,120
Operating loss	(15,659)	(18,130)
Interest expense, net	20
Other expense	2	12
Loss before income tax provision	(15,681)	(18,142)
Income tax provision	76	19
Net loss	(15,757)	(18,161)
Total comprehensive loss	$ (15,757)	$ (18,161)
Net loss per share - basic and diluted	$ (1.18)	$ (1.40)
Weighted average, shares outstanding - basic and diluted	13,337,560	12,945,968

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Ordinary Shares [Member]	Deferred Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ (706)		$ 54	$ 36,626	$ (37,386)
Balance, shares at Dec. 31, 2014			40,000
Capitalization of amounts due to Parent pursuant to 2015 Debt Conversion of Presbia Holdings	1,559			1,559
Initial public offering, net of issuance costs	36,844	$ 13		36,831
Initial public offering, net of issuance costs, shares		13,333,334
Stock-based compensation (including allocation from the Parent)	2,306			2,306
Cancellation of deferred shares pursuant to distribution of Parent's assets, shares			(6)
Issuance of restricted stock, shares		22,143
Bonus payments by Parent on behalf of Presbia PLC	183			183
Net loss	(18,161)				(18,161)
Balance at Dec. 31, 2015	22,025	$ 13	$ 54	77,505	(55,547)
Balance, shares at Dec. 31, 2015		13,355,477	39,994
Stock-based compensation (including allocation from the Parent)	2,171			2,171
Issuance of restricted stock, shares		65,450
Net loss	(15,757)				(15,757)
Balance at Dec. 31, 2016	$ 8,439	$ 13	$ 54	$ 79,676	$ (71,304)
Balance, shares at Dec. 31, 2016		13,420,927	39,994

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flow from operating activities:
Net loss	$ (15,757)	$ (18,161)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	253	173
Inventory provisions	278	169
Loss on disposal of fixed assets	4	12
Stock-based compensation (including allocation from Presbia Holdings in 2015)	2,171	2,306
Imputed interest expense	37
Non-cash interest expense on funding from the Parent		1
Non-cash operating expenses allocated from the Parent		183
Changes in operating assets and liabilities:
Accounts receivable	113	(91)
Inventory	(149)	(222)
Prepaid expenses and other current assets	16	(120)
Other assets	(98)	9
Accounts payable and other current liabilities	(301)	44
Income taxes payable	8	16
Deferred rent	59	(15)
Due to related parties	(37)	43
Net cash used in operating activities	(13,403)	(15,653)
Cash flow from investing activities:
Purchase of intangible assets	(665)
Purchases of property and equipment	(140)	(196)
Net cash used in investing activities	(805)	(196)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares upon initial public offering, net of underwriting costs		38,750
Deferred offering costs	(167)	(2,431)
Proceeds from sale of equipment	1
Funding from the Parent		1,141
Net cash (used in) provided by financing activities	(166)	37,460
Net (decrease) increase in cash	(14,374)	21,611
Effect of exchange rate on cash	(42)
Cash balance at beginning of period	21,749	138
Cash balance at end of period	7,333	21,749
Supplemental disclosure of cash flow information:
Cash paid for income taxes	50	3
Supplemental disclosures of non-cash investing and financing activities:
Deferred offering costs included in accounts payable and other current liabilities	91
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions		$ 1,559
Note Payable To Neoptics AG [Member]
Supplemental disclosures of non-cash investing and financing activities:
Remaining installments payable to Neoptics AG pursuant to asset purchase agreement	$ 981

Basis of Presentation and Descr

Basis of Presentation and Description of the Business	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Description of the Business	(1) Basis of Presentation and Description of the Business Presbia PLC (the “Company” or “Presbia PLC”), an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares of €1.00 each for 40,000 Euro (approximately $54,000) for the purpose of consummating an initial public offering (“IPO”) of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited. On November 30, 2014, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by certain subsidiaries of Presbia Ireland, Limited at that time to equity (“2014 Debt Conversion”). In the 2014 Debt Conversion, approximately $23.5 million of outstanding intercompany debt owed to Presbia Holdings was converted to equity of Presbia Ireland, Limited. On January 14, 2015, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by a subsidiary of Presbia Ireland, Limited at that time to equity (the “2015 Debt Conversion”) in the amount of approximately $1.6 million. On January 14, 2015, the Parent contributed all the share capital in issue in Presbia Ireland, Limited to Presbia PLC (the “2015 Capital Contribution”) in exchange for 9,166,667 ordinary shares of US$0.01 each of Presbia PLC. The aggregate 9,166,667 ordinary shares of Presbia PLC have been reflected as issued and outstanding as of the earliest date of the periods presented for purposes of computation of basic and diluted net loss per share. On February 3, 2015, Presbia PLC completed its initial public offering (“IPO”) of 4,166,667 of its ordinary shares at a price to the public of $10.00 per ordinary share and commenced trading on The NASDAQ Global Market under the symbol LENS. The Parent acquired 500,000 ordinary shares from the public offering. The net proceeds from the IPO consisted of aggregate gross proceeds of approximately $41.7 million less underwriting discounts and commissions of approximately $2.9 million and other issuance costs of approximately $2.0 million resulting in net proceeds of approximately $36.8 million. On August 3, 2015, Presbia Holdings completed the distribution of its holdings of 9,666,667 ordinary shares of Presbia PLC to its ordinary shareholders for the purpose of dissolving Presbia Holdings on November 25, 2015 and ceasing to be the Parent of Presbia PLC. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC, Presbia Ireland, Limited, organized in Ireland, Presbia Investments organized in the Cayman Islands and Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. All amounts are shown in U.S. dollars. The Company, which began to be formed on June 29, 2007, has developed and is marketing a surgical solution to the age-related vision condition known as presbyopia. The Company’s primary objectives have been twofold: (1) achieve commercial success in those parts of the world where the Company’s surgical procedure has been approved by regulatory agencies and (2) successfully apply to the United States Food and Drug Administration (the “FDA”) for the authorization to market and manufacture the surgical procedure in the United States. Other than the FDA clinical trials that begun in 2014 and will continue to at least 2018, this procedure is currently not authorized by the FDA and may not be manufactured, sold, distributed or surgically performed on any individual in the United States. The Company’s principal revenue generating activity is the sale of the Company’s microlens to approved ophthalmologist physicians who, in turn, perform the surgical procedure on their patient base. Presbia is authorized to sell, market and perform this procedure in 40 countries through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. Activities to-date have consisted primarily of research and development and expansion of its commercial activities in selected markets outside the United States. Stock-based compensation expenses recognized by the Parent that were incurred to benefit the Company have been allocated to the Company (see Note 10). The financial information in these statements may not include all of the expenses that would have been incurred had the Company been a separate, stand-alone publicly traded entity. Liquidity The Company has incurred significant operating losses since inception and has relied on funding from its Parent to fund its operations prior to its initial public offering concluded on February 3, 2015. At December 31, 2016, the Company has an accumulated deficit of $71.3 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. Based on our current business plan, we believe that our cash and cash equivalents at December 31, 2016, coupled with net proceeds from our “rights offering” of $10.5 million and with anticipated revenues outside of the United States will be sufficient to satisfy our anticipated cash requirements, including capital expenditures, working capital requirements, long term debt and other liquidity requirements through at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates. Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting, operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Since 2013, the Company has viewed and managed its operations and business as one segment through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. and its wholly-owned Irish entity, Presbia Ireland, Limited, operating primarily in South Korea, Australia, the Netherlands, Ireland and Canada. Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gain was $1,000 for the year ended December 31, 2016, and aggregate foreign exchange loss was $6,000 for the year ended December 31, 2015. Reclassifications Certain prior year balances within the consolidated financial statements have been reclassified to conform to current year presentation. Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash. Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. The Company’s debt obligation approximates fair value as a result of imputed interest which approximates prevailing market rates. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values. Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2016 and 2015, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts. Inventory The Company accounts for inventory at the lower of market or cost. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss. Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment. Intangible Assets On August 2, 2016, Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement (the “Agreement”) with Neoptics AG (“Neoptics”) pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and the US Dollar on August 2, 2016) payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The assets acquired include patents, pending patents, and other immaterial assets. Effective August 2, 2016, the Company became responsible for all expenses associated with such assets. Pursuant to the terms of the Agreement, the acquisition closed on August 2, 2016. Substantially all of the fair value of the gross assets acquired is concentrated in the acquired intellectual property rights or patents and not in the trademarks, documents or electronic data obtained from the Seller. The Company determined the intellectual property right or patents were akin to inputs within the scope of ASC 805 “Business Combinations” and that no substantive processes were acquired in the assets acquisition. Therefore, the Company applied the asset acquisition accounting guidance in ASC 805-50-30 “Initial Measurement of Acquisition of Assets Rather than a Business.” We paid $0.6 million in cash in exchange for these patents and patent applications in the year ended December 31, 2016. The useful life of the patents was determined to be 12 years and 4 months and will be amortized through November 25, 2028. The Company recorded amortization expense of approximately $52,000 with net carrying amount of approximately $1,477,000 as of December 31, 2016. The annual future amortization is approximately $124,000 through 2028. As part of this transaction, we established a note payable of $859,000 (Note 6). Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2016 and 2015, the Company capitalized $0 associated with website development. Amortization expense of $15,000, and $14,000 was recorded in 2016 and 2015, respectively. Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the years ended December 31, 2016 and 2015. Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. In the years ended December 31, 2016 and 2015 there were three and six customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2016, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. Laser Center Revenues The Company recognized revenues of $14,000 and $109,000 from laser centers during the years ended December 31, 2016 and 2015, respectively. The Company recognizes revenue from these laser centers based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Distributor Revenues During the years ended December 31, 2016 and 2015, approximately $0, and $44,000 of revenue were recognized from distributor arrangements. The distributor arrangements include certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. The Company has not had any significant rejected shipments or warranty claims. In 2013 the Company changed its commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense. Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Additionally, the fair value of restricted stock units is determined using a Monte Carlo Simulation, or “MCS”, methodology, which considers the separate probabilities that of the price thresholds or market conditions will be achieved under the Restricted Stock Units Plan guidelines. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis (net of estimated forfeitures) over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company. Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for a capital raise are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the capital raise is concluded as a reduction of the proceeds of the capital raise as part of additional paid in capital. The Company capitalized approximately $0.2 million of rights offering costs in the fourth quarter of 2016 as part of other current assets on the balance sheet as of December 31, 2016. Income Taxes For the years ended December 31, 2016 and 2015, the Company was generally not subject to income taxes, as income or loss was either passed-through and included in the income tax returns of the Company’s shareholders or otherwise not subject to tax under local statute or rulings. As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the consolidated statements of operations and comprehensive loss in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $198,000, and $79,000 as part of sales and marketing expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2016 and 2015, respectively. Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s Recently Adopted Accounting Standards In June 2014, the FASB issued ASU 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In August 2015, the FASB issued ASU 2015-15, Interest – Imputation of Interest Future Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the Financial Accounting Standards Board issued ASU 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	(3) Inventory The Company maintains a serial number tracking system that measures shelf life such that no lens that has aged beyond four years shall be delivered to a customer. During the years ended December 31, 2016 and 2015, inventory write-downs reflecting excess quantities on hand were recognized in the amount of $278,000 and $169,000, respectively, based on the age of the lens inventory, inserters, accessories and the refractive mix of the inventory. Finished goods inventory consists of the following (in thousands): December 31, 2016 2015 Lenses $ 175 $ 294 Accessories 127 136 Inventory $ 302 $ 430

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment, net consist of the following (in thousands): December 31, 2016 2015 Office equipment and computers $ 78 $ 74 Leasehold improvements 168 142 Production equipment and facilities 788 752 Software 62 58 Construction In Process — 1 Furniture and vehicles 227 167 1,323 1,194 Less: accumulated depreciation (596 ) (419 ) Property and equipment, net $ 727 $ 775 Depreciation and amortization expense related to property and equipment for the years ended December 31, 2016 and 2015 was $186,000 and $159,000, respectively.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Assets	(5) Other Assets Other assets consist of the following (in thousands): December 31, 2016 2015 Deposits and other assets $ 126 $ 63 $ 126 $ 63

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Note Payable	(6) Note Payable Note payable is summarized as follows (in thousands): December 31, 2016 2015 Noninterest bearing note payable to Neoptics A.G. $ 981 $ — Less present value discount (122 ) — Note payable, net 859 — Less current portion 490 — Note payable, long term $ 369 $ — Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement with Neoptics AG pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and US Dollar on August 2, 2016), bearing no interest and payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The Company recorded the intangible asset and a loan discount using a rate of 9%. The remaining liability is recorded in the Company’s balance sheet, net of unamortized discount of $159,000 at December 31, 2016. The discount on the note payable is being amortized to imputed interest expense over the life of the note.

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2016
Other Liabilities Current [Abstract]
Other Current Liabilities	(7) Other Current Liabilities Other current liabilities consist of the following as of the dates set forth below (in thousands): December 31, 2016 2015 Accrued payroll related and bonuses $ 392 $ 307 Accrued professional fees 71 33 Accrued utilities and outside services — 90 Accrued other expense 67 61 Income tax payable 52 44 Deferred tax liability — 34 $ 582 $ 569

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Loss per Share	(8) Loss per Share Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period, less unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2016 2015 Net Loss $ (15,757 ) $ (18,161 ) Net income allocated to participating securities — — Net loss allocated to common shareholders $ (15,757 ) $ (18,161 ) Weighted average shares outstanding - basic and diluted 13,337,560 12,945,968 Basic and diluted net loss per share $ (1.18 ) $ (1.40 ) Antidilutive securities, which consist of options and restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of 1,082,916 and 1,044,743 weighted average shares for the fiscal years ended December 31, 2016 and 2015, respectively.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Shareholders' Equity	(9) Shareholders’ Equity Ordinary Shares As of December 31, 2016, our authorized share capital includes $400,000 and €40,000 divided into 350,000,000 ordinary shares of $0.001 each, which we refer to as the ordinary shares. The rights and preferences of the ordinary shares are as follows: (i) subject to the right of the Company to set record dates for the purposes of determining the identity of shareholders entitled to notice of and/or to vote at a general meeting, the right to attend and speak at any general meeting of the Company and to exercise one vote per ordinary share held at any general meeting of the Company; (ii) the right to participate pro rata in all dividends declared by the Company; and (iii) the right, in the event of the Company’s winding up, to participate pro rata in the total assets of the Company. The rights attaching to the ordinary shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with our articles of association. Deferred Ordinary Shares Capital related to Presbia PLC at December 31, 2014 consisted of ordinary shares of €1.00 each (“Euro Ordinary Shares”) of $54,000, €1.00 par value, 40,000 authorized and issued with effective date of formation of February 6, 2014 (paid-in on January 10, 2014 with $1.35: €1.00), being $54,000 in aggregate. On January 14, 2015 the Company amended its memorandum and articles of association, resulting in the re-designation of the 40,000 Euro Ordinary Shares as deferred ordinary shares (“Deferred Ordinary Shares”). In August 2015, the Company cancelled 6 Deferred Ordinary Shares pursuant to the distribution of assets held by Presbia Holdings to its ordinary shareholders and 39,994 Deferred Ordinary Shares held by Presbia Holdings were transferred to Richard Ressler. Our articles of association provide that the holders of Deferred Ordinary Shares shall not be entitled to receive notice of, nor attend, speak or vote at, any general meeting of the Company and the holders of Deferred Ordinary Shares shall not be entitled to receive any dividend or distribution declared, made or paid or any return of capital or to any further or other right of participation in the assets of the Company. On a winding up of, or other return of capital (other than on a redemption of any class of shares in the capital of the Company) by the Company, the holders of Deferred Ordinary Shares are entitled to participate in such return of capital or winding up, such entitlement to be limited to the repayment of the amount paid up or credited as paid up on such Deferred Ordinary Shares, which shall be paid only after the holders of ordinary shares have received payment in respect of such amount as is paid up or credited as paid up on those ordinary shares held by them at that time, plus the payment in cash of $5,000,000 on each such ordinary share. The rights attaching to the Deferred Ordinary Shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with our articles of association. Preferred Shares Our authorized share capital also includes 50,000,000 preferred shares of $0.001 each, which we refer to as preferred shares. As of December 31, 2016, no preferred shares have been issued. Our articles of association authorize our Board, without shareholder approval, to determine the terms of the preferred shares that may be issued by us. Our Board is authorized, without obtaining any shareholder vote or consent, unless expressly provided by the terms of that class or series of class of shares, to provide from time to time for the issuance of ordinary shares or other classes or series of shares and to establish the characteristics of each such other class or series, including the number of shares, designations, relative voting rights, dividend rights, liquidation and other rights, redemption, repurchase or exchange rights and any other preferences and relative, participating, optional or other rights and limitations not inconsistent with applicable law.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options	(10) Stock Options Share Based Awards Equity Issued by Parent Liquidation of Presbia Holdings In May 2015, pursuant to a plan to liquidate the Parent and distribute all of its assets to its ordinary shareholder by August 2015, the shareholders of the Parent approved a plan in which all options and unvested restricted shares outstanding as of May 13, 2015 were to become fully vested immediately, and, in the case of the options, the expiration date of the options were accelerated to June 15, 2015. By November 2015, the Company’s Parent was dissolved, and, as such, no share-based compensation expense was recognized in the year ended December 31, 2016. Options Prior to 2014, the Parent granted options to purchase its ordinary shares to both employees and non-employees of the Company and share-based compensation related to such awards was recognized as expense in the Company’s Consolidated Statements of Operation and Comprehensive Loss for all reported periods including the year ended December 31, 2015. As of December 31, 2015, there were no options outstanding to purchase the Parent’s ordinary shares, as the expiration of the options were accelerated to June 15, 2015. As a result of the acceleration of the vesting dates of these options, incremental stock-based compensation expense was recognized in the amount of approximately $21,000. Restricted Shares No restricted shares were granted by the Parent during the year ended December 31, 2015, and, similarly, as of June 15, 2015, the Parent accelerated vesting of all unvested restricted shares. As of December 31, 2015, there were no unvested restricted shares of the Parent and approximately $104,000 was recognized as incremental stock-based compensation expense due to the acceleration of the vesting dates in the year ended December 31, 2015. Unrecognized Share-based Compensation As of December 31, 2015 and 2016, there was no unrecognized stock-based compensation expense related to the awards issued by the Parent. Equity Issued by Presbia PLC Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted stock units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 2,200,000 ordinary shares were authorized for issuance under the Presbia Incentive Plan of which approximately 343,407 were available on December 31, 2016 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the Presbia Incentive Plan awards, and generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2016 and 2015. Year Ended December 31, 2016 2015 Research and development $ 259 $ 223 General and administrative 1,549 1,762 Sales and marketing 363 165 $ 2,171 $ 2,150 Options The following table sets forth the Company’s option activity for the year ended December 31, 2016: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2016 1,084,583 $ — — Exercised — $ — — Forfeited/cancelled/expired (34,583 ) $ 8.46 — Balance, December 31, 2016 1,050,000 $ 9.77 — Vested, December 31, 2016 339,732 $ 9.81 — Unvested, December 31, 2016 710,268 $ 9.74 — Exercisable, December 31, 2016 339,732 $ 9.81 — Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under ASC 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award. The following table presents the grant date assumptions used in the Black-Scholes model for determining the fair value of 0 and 1,032,500 employee options issued during the years ended December 31, 2016 and 2015, respectively: Year Ended December 31, 2016 2015 Stock price per share $ — $4.39 - $10.00 Term — 5.5 - 6.5 Yrs. Volatility — 69.8% - 84.6% Dividends — — Risk-free rate — 1.3% - 2.0% The weighted-average grant date fair values of employee options granted during the years ended December 31, 2016 and 2015 was $0 and $6.74 respectively, per share. For those options granted to employees, stock-based compensation expense was based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. The forfeiture rate, which reduces the amount of expense that is recorded reflecting the anticipated number of options that ultimately will vest in future periods, is subject to review and may be adjusted based upon experience. During 2015 and for the three months ended March 31, 2016, a 5% annualized forfeiture rate was applied. Based upon review of pre-vesting forfeitures, commencing with the second quarter of 2016, the forfeiture rate was reduced to 3%. Non-Employee Options During the years ended December 31, 2016 and 2015, 0 and 78,000 options, respectively, were granted to non-employee consultants and medical advisors. The following assumptions were used in the Black-Scholes valuation model to determine the option fair values: Year Ended December 31, 2016 2015 Stock price per share $2.50 -$3.49 $ 5.26 Expected term 8.2 - 9.3 Yrs. 9.2 - 9.9 Yrs. Volatility 66.1% - 92.6% 75.8% - 78.8% Dividends — — Risk-free rate 1.4% - 2.5% 2.3% In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the preceding table. Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to a forfeiture rate of 3%. As described in the preceding section, the annualized forfeiture rate was reduced from 5% to 3%. Restricted Shares Consistent with the Company’s director compensation policy, the Company’s board of directors approved the grant of 65,450 restricted ordinary shares of the Company during the year ended December 31, 2016, with a grant date weighted average fair value of $3.50, a five-year vesting period consisting of 20% on each annual anniversary date commencing one-year following the date of grant. The following table sets forth the Company’s restricted share activity for the year ended December 31, 2016: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2015 20,289 $ — Granted 65,450 $ 3.50 Vested (4,057 ) $ 3.50 Forfeited/cancelled — $ — Unvested, December 31, 2016 81,682 $ — Restricted Stock Units During the year ended December 31, 2016, the Board of Directors approved the award of 787,500 restricted stock units (“RSU” or “RSU’s” or “RSU Plan”), respectively, to officers and employees in accordance with the guidelines provided by the Presbia Incentive Plan, which includes a provision that the recipient must be employed as a condition of vesting. The Presbia RSU Plan authorizes the issuance of 20% of each recipient’s total RSU award for the first occurrence that the closing price of the Company’s ordinary shares exceed, for a period of 20 consecutive business days, price thresholds of $10.00, $15.00, $20.00, $25.00 and $30.00, respectively. The RSU Plan also provides for a one-year “wait” or service period prior to any vesting permitted under the plan. The RSU Plan has a seven-year expiration period following the date of the grant. Fair value of the RSU’s awarded were determined using a MCS methodology, which considers the separate probabilities that each of the price thresholds or market conditions will be achieved under the RSU Plan guidelines. Each probability is weighted by its respective price threshold, or its intrinsic value, which provides the basis for an aggregate fair value. The Company used the following key inputs in determining the fair value using the MCS model: (i) the volatility of the entity’s common stock and (ii) the closing price of the entity’s stock as of the measurement date of the RSU award. In accordance with GAAP, the Company recognizes as stock-based compensation expense, using a straight-line attribution method, the aggregate fair value over future periods based upon the respective derived service periods and fair values for each of the price thresholds as provided by the MCS model. A 3% forfeiture rate was applied to account for future cancellations and forfeitures. During the year ended December 31, 2016, approximately $467,000 was recorded as stock-based compensation related to the RSU Plan. No such expense was recognized in the same periods in 2015. During the year ended December 31, 2016, 787,500 restricted stock unit were granted to new employees. The following table sets forth the Company’s RSU activity for the year ended December 31, 2016: Unvested Number of Weighted Average Fair Shares Value per Share Balance, December 31, 2015 — $ — Granted 787,500 $ 3.07 Vested — $ — Forfeited/cancelled (68,500 ) $ 2.84 Unvested, December 31, 2016 719,000 $ 3.10 As of December 31, 2016, 719,000 RSU’s were outstanding with none vested. Unrecognized Share-based Compensation As of December 31, 2016 and 2015, there were $3.4 million and $4.6 million, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 2.0 and 3.7 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $0.3 million and $0.1 million, respectively, and is expected to be recognized over the weighted average vesting periods of 2.6 and 4.4 years, respectively. As of December 31, 2016, there was approximately $1.5 million of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 2.2 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	(11) Related Party Transactions The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2016 2015 Payable to related parties-current: Management services provided by related parties $ 18 $ 55 Total $ 18 $ 55 Mr. Ressler is a member of the Company’s Board of Directors and had served as the Chairman of the Board of the Parent since the Parent’s formation in 2007 and along with immediate family members had a controlling interest in a partnership that controlled the Parent, prior to its dissolution in November 2015. In January 2015, we effected the 2015 Debt Conversion described under “Part I, Item I, Business—Corporate History and Information.” In the 2015 Debt Conversion, approximately $1.6 million, representing the balance of outstanding intercompany debt owed to Presbia Holdings by a subsidiary of Presbia Ireland, Limited at that time, was converted to equity of such subsidiary. In addition, in January 2015, Presbia Holdings contributed all of the shares in issue of Presbia Ireland, Limited to Presbia PLC, an Irish incorporated public limited company, in exchange for 9,166,667 ordinary shares of Presbia PLC. Presbia Holdings purchased an aggregate of 500,000 ordinary shares in our initial public offering in February 2015. In May 13, 2015, the board of directors of Presbia Holdings approved the liquidation of Presbia Holdings, which liquidation was subsequently approved by the shareholders of Presbia Holdings on May 13, 2015. In connection with the liquidation, on August 3, 2015, Presbia Holdings distributed, by way of a dividend in specie, the 9,666,667 ordinary shares of the Company that it held as of that date to its equity holders, pro rata based on each such equity holder’s equity ownership in Presbia Holdings. In July 2015, Presbia Holdings incurred and paid bonus payments of approximately $183,000 on behalf of Presbia PLC in connection with the Liquidation. Since 2011, Orchard Capital Corporation (“Orchard”), which is wholly-owned by Mr. Ressler, has provided financial analysis and bookkeeping, accounting, legal, compliance and directorial services to the Company pursuant to a Services Agreement. During the years ended December 31, 2016, and 2015, the Company recognized general and administrative expense of $14,000 and $139,000, respectively, for services invoiced by Orchard. As of December 31, 2016 and 2015, amounts due to Orchard for management and accounting services amounted to $4,000 and $2,000, respectively. Commencing during the second quarter of 2013, the Company has received human resources management services, payroll services, IT support and risk management services from CIM Group, an entity in which Mr. Ressler has a controlling interest. The Company has incurred charges of $73,000 and $185,000 payable to CIM Group for such services for the years ended December 31, 2016 and 2015, respectively. As of December 31, 2016 and 2015, amounts due to CIM Group for human resources, payroll, information technology and legal services amounted to $14,000 and $53,000, respectively.

Operating Segments and Geograph

Operating Segments and Geographic Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Operating Segments and Geographic Information	(12) Operating Segments and Geographic Information The Company operates in one operating segment, the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. Revenue originating in the United States is limited to intercompany transactions that do not result in any revenue generating activities to any individual or physician in the United States, and these amounts are eliminated upon consolidation. The operating losses in the United States result primarily from research and development and general and administrative costs while the operating losses in the foreign operations result primarily from sales and marketing costs and an allocation of general and administrative costs to foreign operations. Revenues from external customers to individual countries are allocated based on the location of the customer. For the periods presented, there was no more than one customer in each individual country. The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2016 2015 Australia $ — $ 2 Brazil — — Canada 1 9 Ireland 14 67 Italy — — Japan — — South Korea — 44 The Netherlands (1 ) 29 UK — 2 Total $ 14 $ 153 Year Ended December 31, Long-lived Assets 2016 2015 U.S. $ 697 $ 736 Foreign 30 39 Total $ 727 $ 775 In the years ended December 31, 2016 and 2015 there were three and six customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2016, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company has a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company receives 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that we believe can be scaled to meet excessive lens demand or a disruption of supply sourced from outside the United States.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) Commitments and Contingencies Facility Leases In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that expires in May 2017, a 26-month sublease of office space in the same California location that commenced in June 2014 and expired in July 2016, a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013, and a 30-month lease in Amsterdam, the Netherlands that commenced on January 1, 2016 and a four-year lease for office space in Irvine, California, that commenced on August 1, 2016 and will expire in September 2020. Aggregate rent expense for the years ended December 31, 2016 and 2015 was $388,000 and $209,000, respectively. The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2017 $ 481 2018 542 2019 552 2020 494 2021 283 Thereafter 119 Total $ 2,471 Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial statements.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(14) Income Taxes The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2016 2015 Current provision: Federal $ — $ — State 4 3 Foreign 72 16 Total current $ 76 $ 19 Deferred provision Federal (255 ) (306 ) State — — Foreign (1,228 ) (1,574 ) Total deferred (1,483 ) (1,880 ) Valuation allowance 1,483 1,880 Total deferred — — Total income tax provision $ 76 $ 19 A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2016 2015 Expected income tax benefit at federal statutory rate 35 % 35 % State tax provision, net of federal benefit 0 % 0 % Foreign rate differential (25 %) (25 %) Pass-through entities 0 % 0 % Change in valuation allowance (10 %) (10 %) Nondeductible expenses 0 % 0 % Other 0 % 0 % Income tax provision (0.0 %) (0.0 %) The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 4,444 $ 3,072 Accrued expenses 195 27 Stock based compensation (11 ) 241 Deferred tax assets 4,628 3,340 Valuation allowance (4,559 ) (3,247 ) Net deferred tax assets 69 93 Deferred tax liabilities: Depreciation (69 ) (93 ) Total deferred tax liabilities (69 ) (93 ) Net deferred tax asset $ — $ — The valuation allowance has been established to offset the Company’s net deferred tax assets, as realization of such assets is not considered to be more likely than not due to the Company’s history of losses and uncertainties regarding the Company’s ability to generate future taxable income sufficient to realize the benefit of these deferred tax assets. The Company has U.S. Federal net operating loss (“NOL”) carryforwards of approximately $2.0 million and $1.6 million for December 31, 2016 and 2015, respectively, subject to potential limitations pursuant to Internal Revenue Code section 382 as discussed below. The federal NOL carryforwards will begin to expire in 2033, unless previously utilized. The Company has NOL carryforwards in Ireland of $30.0 million and $20.2 million for December 31, 2016 and 2015, respectively, which can be carried forward indefinitely. Pursuant to Sections 382 of the Internal Revenue Code (the “Code”), annual use of the Company’s NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period. An ownership change may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income and tax. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain shareholders. Presbia Cooperatief U.A. is a Dutch Company that received an advance ruling with the Tax and Customs Administration that was in effect from January 1, 2012 to December 31, 2015. As of December 31, 2016 and December 31, 2015, the Company does not have any unrecognized tax benefits. The Company does not anticipate a significant increase in the unrecognized tax benefits over the next 12 months. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of December 31, 2016 and December 31, 2015, the Company did not have any tax related accrued interest and penalties on its balance sheet or on its statement of operations. Due to net operating loss carryovers, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for years 2008 through 2016. The foreign income tax returns are open to examination for the years 2012 through 2016 .

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	(15) Subsequent Events On December 5, 2016, the Company filed with the SEC Form S-1 Registration Statement under the Securities Act of 1933 for the purpose of distributing to holders of the Company’s ordinary shares non-transferable and non-tradeable subscription rights to purchase ordinary shares (“rights offering”). Each shareholder received one subscription right for each ordinary share owned at 5:00 PM Eastern on February 6, 2017, the record date for the rights offering. Each subscription right entitled its holder to purchase 0.335297256 ordinary shares at a subscription price of $3.00 per whole share (“basic subscription right”). Shareholders that exercised their basic subscription rights in full were entitled to an over-subscription privilege to purchase a portion of the unsubscribed ordinary ordinary shares at the subscription price, subject to proration (“over-subscription privilege”). Shareholders acquired 3,611,764 additional shares from the rights offering. The net proceeds consisted of aggregate gross proceeds of approximately $10.8 million less offering costs of approximately $0.3 million resulting in net proceeds of approximately $10.5 million.

Basis of Presentation and Des22

Basis of Presentation and Description of the Business (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Liquidity	Liquidity The Company has incurred significant operating losses since inception and has relied on funding from its Parent to fund its operations prior to its initial public offering concluded on February 3, 2015. At December 31, 2016, the Company has an accumulated deficit of $71.3 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. Based on our current business plan, we believe that our cash and cash equivalents at December 31, 2016, coupled with net proceeds from our “rights offering” of $10.5 million and with anticipated revenues outside of the United States will be sufficient to satisfy our anticipated cash requirements, including capital expenditures, working capital requirements, long term debt and other liquidity requirements through at least the next twelve months.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates.
Segment Information	Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting, operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Since 2013, the Company has viewed and managed its operations and business as one segment through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. and its wholly-owned Irish entity, Presbia Ireland, Limited, operating primarily in South Korea, Australia, the Netherlands, Ireland and Canada.
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gain was $1,000 for the year ended December 31, 2016, and aggregate foreign exchange loss was $6,000 for the year ended December 31, 2015.
Reclassifications	Reclassifications Certain prior year balances within the consolidated financial statements have been reclassified to conform to current year presentation.
Concentrations of Credit Risks	Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash.
Fair Value Of Financial Instruments Policy	Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. The Company’s debt obligation approximates fair value as a result of imputed interest which approximates prevailing market rates. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values.
Cash	Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2016 and 2015, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts.
Inventory	Inventory The Company accounts for inventory at the lower of market or cost. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment.
Intangible Assets	Intangible Assets On August 2, 2016, Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement (the “Agreement”) with Neoptics AG (“Neoptics”) pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and the US Dollar on August 2, 2016) payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The assets acquired include patents, pending patents, and other immaterial assets. Effective August 2, 2016, the Company became responsible for all expenses associated with such assets. Pursuant to the terms of the Agreement, the acquisition closed on August 2, 2016. Substantially all of the fair value of the gross assets acquired is concentrated in the acquired intellectual property rights or patents and not in the trademarks, documents or electronic data obtained from the Seller. The Company determined the intellectual property right or patents were akin to inputs within the scope of ASC 805 “Business Combinations” and that no substantive processes were acquired in the assets acquisition. Therefore, the Company applied the asset acquisition accounting guidance in ASC 805-50-30 “Initial Measurement of Acquisition of Assets Rather than a Business.” We paid $0.6 million in cash in exchange for these patents and patent applications in the year ended December 31, 2016. The useful life of the patents was determined to be 12 years and 4 months and will be amortized through November 25, 2028. The Company recorded amortization expense of approximately $52,000 with net carrying amount of approximately $1,477,000 as of December 31, 2016. The annual future amortization is approximately $124,000 through 2028. As part of this transaction, we established a note payable of $859,000 (Note 6). Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2016 and 2015, the Company capitalized $0 associated with website development. Amortization expense of $15,000, and $14,000 was recorded in 2016 and 2015, respectively.
Comprehensive Loss	Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the years ended December 31, 2016 and 2015.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. In the years ended December 31, 2016 and 2015 there were three and six customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2016, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. Laser Center Revenues The Company recognized revenues of $14,000 and $109,000 from laser centers during the years ended December 31, 2016 and 2015, respectively. The Company recognizes revenue from these laser centers based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Distributor Revenues During the years ended December 31, 2016 and 2015, approximately $0, and $44,000 of revenue were recognized from distributor arrangements. The distributor arrangements include certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. The Company has not had any significant rejected shipments or warranty claims. In 2013 the Company changed its commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives.
Clinical Trials	Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
Stock-Based Compensation	Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Additionally, the fair value of restricted stock units is determined using a Monte Carlo Simulation, or “MCS”, methodology, which considers the separate probabilities that of the price thresholds or market conditions will be achieved under the Restricted Stock Units Plan guidelines. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis (net of estimated forfeitures) over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company.
Deferred Offering Costs	Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for a capital raise are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the capital raise is concluded as a reduction of the proceeds of the capital raise as part of additional paid in capital. The Company capitalized approximately $0.2 million of rights offering costs in the fourth quarter of 2016 as part of other current assets on the balance sheet as of December 31, 2016.
Income Taxes	Income Taxes For the years ended December 31, 2016 and 2015, the Company was generally not subject to income taxes, as income or loss was either passed-through and included in the income tax returns of the Company’s shareholders or otherwise not subject to tax under local statute or rulings. As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.
Advertising Costs	Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the consolidated statements of operations and comprehensive loss in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $198,000, and $79,000 as part of sales and marketing expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2016 and 2015, respectively.
Risks and Uncertainties	Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In June 2014, the FASB issued ASU 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In August 2015, the FASB issued ASU 2015-15, Interest – Imputation of Interest
Future Accounting Pronouncements	Future Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the Financial Accounting Standards Board issued ASU 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Summary of Finished Goods Inventory	Finished goods inventory consists of the following (in thousands): December 31, 2016 2015 Lenses $ 175 $ 294 Accessories 127 136 Inventory $ 302 $ 430

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): December 31, 2016 2015 Office equipment and computers $ 78 $ 74 Leasehold improvements 168 142 Production equipment and facilities 788 752 Software 62 58 Construction In Process — 1 Furniture and vehicles 227 167 1,323 1,194 Less: accumulated depreciation (596 ) (419 ) Property and equipment, net $ 727 $ 775

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Summary of Other Assets	Other assets consist of the following (in thousands): December 31, 2016 2015 Deposits and other assets $ 126 $ 63 $ 126 $ 63

Note Payable (Tables)

Note Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Summary of Note Payable	Note payable is summarized as follows (in thousands): December 31, 2016 2015 Noninterest bearing note payable to Neoptics A.G. $ 981 $ — Less present value discount (122 ) — Note payable, net 859 — Less current portion 490 — Note payable, long term $ 369 $ —

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Other Liabilities Current [Abstract]
Summary of Other Current Liabilities	Other current liabilities consist of the following as of the dates set forth below (in thousands): December 31, 2016 2015 Accrued payroll related and bonuses $ 392 $ 307 Accrued professional fees 71 33 Accrued utilities and outside services — 90 Accrued other expense 67 61 Income tax payable 52 44 Deferred tax liability — 34 $ 582 $ 569

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2016 2015 Net Loss $ (15,757 ) $ (18,161 ) Net income allocated to participating securities — — Net loss allocated to common shareholders $ (15,757 ) $ (18,161 ) Weighted average shares outstanding - basic and diluted 13,337,560 12,945,968 Basic and diluted net loss per share $ (1.18 ) $ (1.40 )

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2016
Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss	The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2016 and 2015. Year Ended December 31, 2016 2015 Research and development $ 259 $ 223 General and administrative 1,549 1,762 Sales and marketing 363 165 $ 2,171 $ 2,150
Schedule of Option Activity	The following table sets forth the Company’s option activity for the year ended December 31, 2016: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2016 1,084,583 $ — — Exercised — $ — — Forfeited/cancelled/expired (34,583 ) $ 8.46 — Balance, December 31, 2016 1,050,000 $ 9.77 — Vested, December 31, 2016 339,732 $ 9.81 — Unvested, December 31, 2016 710,268 $ 9.74 — Exercisable, December 31, 2016 339,732 $ 9.81 —
Schedule of Restricted Shares Activity	The following table sets forth the Company’s restricted share activity for the year ended December 31, 2016: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2015 20,289 $ — Granted 65,450 $ 3.50 Vested (4,057 ) $ 3.50 Forfeited/cancelled — $ — Unvested, December 31, 2016 81,682 $ —
Schedule of RSU Activity	The following table sets forth the Company’s RSU activity for the year ended December 31, 2016: Unvested Number of Weighted Average Fair Shares Value per Share Balance, December 31, 2015 — $ — Granted 787,500 $ 3.07 Vested — $ — Forfeited/cancelled (68,500 ) $ 2.84 Unvested, December 31, 2016 719,000 $ 3.10
Employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	The following table presents the grant date assumptions used in the Black-Scholes model for determining the fair value of 0 and 1,032,500 employee options issued during the years ended December 31, 2016 and 2015, respectively: Year Ended December 31, 2016 2015 Stock price per share $ — $4.39 - $10.00 Term — 5.5 - 6.5 Yrs. Volatility — 69.8% - 84.6% Dividends — — Risk-free rate — 1.3% - 2.0%
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	During the years ended December 31, 2016 and 2015, 0 and 78,000 options, respectively, were granted to non-employee consultants and medical advisors. The following assumptions were used in the Black-Scholes valuation model to determine the option fair values: Year Ended December 31, 2016 2015 Stock price per share $2.50 -$3.49 $ 5.26 Expected term 8.2 - 9.3 Yrs. 9.2 - 9.9 Yrs. Volatility 66.1% - 92.6% 75.8% - 78.8% Dividends — — Risk-free rate 1.4% - 2.5% 2.3%

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2016 2015 Payable to related parties-current: Management services provided by related parties $ 18 $ 55 Total $ 18 $ 55

Operating Segments and Geogra31

Operating Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Revenues Generated from External Customers and Long-lived Assets by Area	The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2016 2015 Australia $ — $ 2 Brazil — — Canada 1 9 Ireland 14 67 Italy — — Japan — — South Korea — 44 The Netherlands (1 ) 29 UK — 2 Total $ 14 $ 153 Year Ended December 31, Long-lived Assets 2016 2015 U.S. $ 697 $ 736 Foreign 30 39 Total $ 727 $ 775

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Schedule of Annual Base Rental Cost Over the Term of the Leases	The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2017 $ 481 2018 542 2019 552 2020 494 2021 283 Thereafter 119 Total $ 2,471

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2016 2015 Current provision: Federal $ — $ — State 4 3 Foreign 72 16 Total current $ 76 $ 19 Deferred provision Federal (255 ) (306 ) State — — Foreign (1,228 ) (1,574 ) Total deferred (1,483 ) (1,880 ) Valuation allowance 1,483 1,880 Total deferred — — Total income tax provision $ 76 $ 19
Schedule of Reconciliation of Federal Statutory Rate to Effective Rate	A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2016 2015 Expected income tax benefit at federal statutory rate 35 % 35 % State tax provision, net of federal benefit 0 % 0 % Foreign rate differential (25 %) (25 %) Pass-through entities 0 % 0 % Change in valuation allowance (10 %) (10 %) Nondeductible expenses 0 % 0 % Other 0 % 0 % Income tax provision (0.0 %) (0.0 %)
Components of Deferred Tax Assets	The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 4,444 $ 3,072 Accrued expenses 195 27 Stock based compensation (11 ) 241 Deferred tax assets 4,628 3,340 Valuation allowance (4,559 ) (3,247 ) Net deferred tax assets 69 93 Deferred tax liabilities: Depreciation (69 ) (93 ) Total deferred tax liabilities (69 ) (93 ) Net deferred tax asset $ — $ —

Basis of Presentation and Des34

Basis of Presentation and Description of the Business - Additional Information (Detail)	Dec. 31, 2016USD ($)Country$ / shares	Aug. 03, 2015shares	Feb. 28, 2015shares	Feb. 03, 2015USD ($)$ / sharesshares	Jan. 14, 2015USD ($)$ / sharesshares	Nov. 30, 2014USD ($)	Feb. 06, 2014USD ($)shares	Feb. 06, 2014EUR (€)€ / sharesshares	Jan. 31, 2015USD ($)	Dec. 31, 2016USD ($)Country$ / shares	Dec. 31, 2015USD ($)$ / shares
Basis Of Presentation [Line Items]
Date of incorporation										Feb. 6, 2014
Number of ordinary shares, value											$ 36,844,000
Ordinary shares, par value | $ / shares	$ 0.001									$ 0.001	$ 0.001
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions					$ 1,600,000	$ 23,500,000			$ 1,600,000		$ 1,559,000
Other issuance costs										$ 167,000	2,431,000
Number of country in which company is authorized to sell, market and perform procedure | Country	40									40
Accumulated deficit	$ (71,304,000)									$ (71,304,000)	$ (55,547,000)
IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares				4,166,667
Ordinary shares, price per share | $ / shares				$ 10
Gross proceeds from issuance of stock				$ 41,700,000
Underwriting discounts and commission costs				2,900,000
Other issuance costs				2,000,000
Net proceeds from issuance of stock				$ 36,800,000
Rights Offering [Member]
Basis Of Presentation [Line Items]
Net proceeds from issuance of ordinary shares	$ 10,500,000
2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares					9,166,667
Ordinary shares, par value | $ / shares					$ 0.01
Presbia Holdings [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares		9,666,667					40,000	40,000
Number of ordinary shares, value							$ 54,000	€ 40,000
Percentage of ownership interests								100.00%
Ordinary shares, par value | € / shares								€ 1
Presbia Holdings [Member] | IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares			500,000	500,000

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Additional Information (Detail) SFr in Millions	Aug. 02, 2016USD ($)Installment	Aug. 02, 2016CHF (SFr)Installment	Dec. 31, 2016USD ($)Customer	Dec. 31, 2015USD ($)Customer
Subsidiary Sale Of Stock [Line Items]
Short-term investment instruments			$ 0	$ 0
Expiration period of each lens			5 years
Payment to acquire patents and patent applications			$ 665,000
Net carrying amount			1,494,000	32,000
Note payable			859,000
Software capitalized			0	0
Amortization expenses of capitalized software			$ 15,000	$ 14,000
Payments collection period			30 days	30 days
Number of customers | Customer			3	6
Revenues			$ 14,000	$ 153,000
Product warranty term			1 year	1 year
Other Current Assets [Member]
Subsidiary Sale Of Stock [Line Items]
Rights offering costs			$ 200,000
Laser Center Revenues [Member]
Subsidiary Sale Of Stock [Line Items]
Revenues			14,000	$ 109,000
Distributor Revenues [Member]
Subsidiary Sale Of Stock [Line Items]
Revenues			$ 0	$ 44,000
Sales [Member] | Customer Concentration [Member]
Subsidiary Sale Of Stock [Line Items]
Concentration risk, percentage			100.00%	100.00%
Patents [Member]
Subsidiary Sale Of Stock [Line Items]
Useful life			12 years 4 months
Intangible asset end of useful life			Nov. 25, 2028
Amortization expense			$ 52,000
Net carrying amount			1,477,000
Annual future amortization through 2028			124,000
Neoptics AG [Member]
Subsidiary Sale Of Stock [Line Items]
Aggregate purchase price of assets	$ 1,500,000	SFr 1.5
Number of equal installments | Installment	3	3
Payment to acquire patents and patent applications			600,000
Note payable			$ 859,000
Neoptics AG [Member] | First Installment [Member]
Subsidiary Sale Of Stock [Line Items]
Asset purchase price payable installment due date	Aug. 2, 2016	Aug. 2, 2016
Neoptics AG [Member] | Second Installment [Member]
Subsidiary Sale Of Stock [Line Items]
Asset purchase price payable installment due date	Dec. 31, 2017	Dec. 31, 2017
Neoptics AG [Member] | Third Installment [Member]
Subsidiary Sale Of Stock [Line Items]
Asset purchase price payable installment due date	Dec. 31, 2018	Dec. 31, 2018
Minimum [Member]
Subsidiary Sale Of Stock [Line Items]
Estimated life of property and equipment			3 years
Customer shipments rejection notifications period			14 days	14 days
Maximum [Member]
Subsidiary Sale Of Stock [Line Items]
Estimated life of property and equipment			10 years
Number of customers | Customer			1
Customer shipments rejection notifications period			45 days	45 days
General and Administrative Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Aggregate foreign exchange gain (loss)			$ 1,000	$ (6,000)
Selling and Marketing Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Advertising costs			$ 198,000	$ 79,000

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory write-downs reflecting excess quantities on hand recognized	$ 278	$ 169

Inventory - Summary of Finished

Inventory - Summary of Finished Goods Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Inventory	$ 302	$ 430
Lenses [Member]
Inventory [Line Items]
Inventory	175	294
Accessories [Member]
Inventory [Line Items]
Inventory	$ 127	$ 136

Property and Equipment, net - S

Property and Equipment, net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,323	$ 1,194
Less: accumulated depreciation	(596)	(419)
Property and equipment, net	727	775
Office equipment and computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	78	74
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	168	142
Production equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	788	752
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	62	58
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		1
Furniture and vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 227	$ 167

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 186,000	$ 159,000

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Deposits and other assets	$ 126	$ 63
Total	$ 126	$ 63

Note Payable - Summary of Note

Note Payable - Summary of Note Payable (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Note payable, net	$ 859
Less current portion	490
Note payable, long term	369
Note Payable To Neoptics AG [Member]
Debt Instrument [Line Items]
Noninterest bearing note payable to Neoptics A.G.	981
Less present value discount	$ (122)

Note Payable - Additional Infor

Note Payable - Additional Information (Detail) - Neoptics AG [Member] SFr in Millions	Aug. 02, 2016USD ($)Installment	Aug. 02, 2016CHF (SFr)Installment	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Aggregate purchase price of assets	$ 1,500,000	SFr 1.5
Number of equal installments | Installment	3	3
Payment description			No interest and payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018.
Loan discount rate			9.00%
Unamortized discount			$ 159,000
First Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Aug. 2, 2016	Aug. 2, 2016
Second Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Dec. 31, 2017	Dec. 31, 2017
Third Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Dec. 31, 2018	Dec. 31, 2018

Other Current Liabilities - Sum

Other Current Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Current [Abstract]
Accrued payroll related and bonuses	$ 392	$ 307
Accrued professional fees	71	33
Accrued utilities and outside services		90
Accrued other expense	67	61
Income tax payable	52	44
Deferred tax liability		34
Total	$ 582	$ 569

Loss per Share - Schedule of Ca

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Basic and diluted net loss per share
Net loss	$ (15,757)	$ (18,161)
Net loss allocated to common shareholders	$ (15,757)	$ (18,161)
Weighted average shares outstanding - basic and diluted	13,337,560	12,945,968
Basic and diluted net loss per share	$ (1.18)	$ (1.40)

Loss per Share - Additional Inf

Loss per Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Antidilutive securities, not included in diluted net loss per calculation	1,082,916	1,044,743

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2016EUR (€)€ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015€ / shares	Aug. 31, 2015shares	Jan. 14, 2015shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014€ / shares
Class Of Stock [Line Items]
Ordinary shares, value authorized	$ 400,000	€ 40,000
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000
Ordinary shares, par value | $ / shares	$ 0.001		$ 0.001
Deferred Ordinary shares | $	$ 54,000		$ 54,000				$ 54,000
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1	$ 1.35	€ 1			$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	39,994				40,000
Deferred ordinary shares, shares issued	39,994	39,994	39,994			40,000
Cash payment for ordinary shareholders upon winding up | $	$ 5,000,000
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000
Preferred shares, par value | $ / shares	$ 0.001		$ 0.001
Preferred shares, shares issued	0	0	0
Richard Ressler
Class Of Stock [Line Items]
Deferred Ordinary Shares Transferred					39,994

Stock Options - Additional Info

Stock Options - Additional Information (Detail) - USD ($)	Jan. 14, 2015	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense				$ 2,171,000	$ 2,150,000
Options outstanding				1,050,000	1,084,583
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted				0	78,000
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period	5 years
Ordinary shares authorized for issuance	2,200,000
Ordinary shares available for future grants and awards				343,407
Award expiration period	10 years
Award expiration date				Jan. 14, 2025
Presbia Incentive Plan [Member] | Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual	20.00%
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted				0	1,032,500
Weighted average grant date fair value				$ 0	$ 6.74
Percentage of estimated forfeiture rate		3.00%	5.00%		5.00%
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted				65,450
Restricted shares/RSUs outstanding				81,682	20,289
Awards vesting period				5 years
Generally vesting percentage for annual				20.00%
Weighted average grant date fair value, granted				$ 3.50
Restricted shares units vested				4,057
Unrecognized compensation expense, weighted average period of recognition				2 years 7 months 6 days	4 years 4 months 24 days
Unrecognized compensation expense related to restricted shares/RSUs				$ 300,000	$ 100,000
Non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Percentage of estimated forfeiture rate		3.00%	5.00%
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense				$ 467,000	0
Restricted shares granted				787,500
Restricted shares/RSUs outstanding				719,000
Award expiration period				7 years
Generally vesting percentage for annual				20.00%
Percentage of estimated forfeiture rate				3.00%
Weighted average grant date fair value, granted				$ 3.07
Consecutive trading days				20 days
Wait or service period				1 year
Restricted shares units vested				0
Unrecognized compensation expense, weighted average period of recognition				2 years 2 months 12 days
Unrecognized compensation expense related to restricted shares/RSUs				$ 1,500,000
Restricted Stock Units [Member] | Threshold Price Period 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				$ 10
Restricted Stock Units [Member] | Threshold Price Period 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				15
Restricted Stock Units [Member] | Threshold Price Period 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				20
Restricted Stock Units [Member] | Threshold Price Period 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				25
Restricted Stock Units [Member] | Threshold Price Period 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				$ 30
Employee and non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense related to options				$ 3,400,000	$ 4,600,000
Unrecognized compensation expense, weighted average period of recognition				2 years	3 years 8 months 12 days
Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense				$ 0
Options outstanding					0
Unrecognized stock-based compensation expense				0	$ 0
Presbia Holdings [Member] | Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Incremental stock-based compensation expense				$ 21,000
Presbia Holdings [Member] | Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Incremental stock-based compensation expense					$ 104,000
Restricted shares granted					0
Restricted shares/RSUs outstanding					0

Stock Options - Share-Based Com

Stock Options - Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 2,171	$ 2,150
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	259	223
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,549	1,762
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 363	$ 165

Stock Options - Schedule of Opt

Stock Options - Schedule of Option Activity (Detail)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Presbia PLC Shares, Beginning Balance	1,084,583
Number of Presbia PLC Shares, Forfeited/cancelled/expired	(34,583)
Number of Presbia PLC Shares, Ending Balance	1,050,000
Number of Presbia PLC Shares, Vested	339,732
Number of Presbia PLC Shares, Unvested	710,268
Number of Presbia PLC Shares, Exercisable	339,732
Weighted Average Exercise Price Per Share, Forfeited/cancelled/expired | $ / shares	$ 8.46
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	9.77
Weighted Average Exercise Price Per Share, Vested | $ / shares	9.81
Weighted Average Exercise Price Per Share, Unvested | $ / shares	9.74
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 9.81

Stock Options - Schedule of Bla

Stock Options - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum		69.80%
Volatility maximum		84.60%
Risk-free rate minimum		1.30%
Risk-free rate maximum		2.00%
Employee options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share		$ 4.39
Expected term		5 years 6 months
Employee options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share		$ 10
Expected term		6 years 6 months
Non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share		$ 5.26
Volatility minimum	66.10%	75.80%
Volatility maximum	92.60%	78.80%
Risk-free rate minimum	1.40%
Risk-free rate maximum	2.50%
Risk-free rate		2.30%
Non-employee options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 2.50
Expected term	8 years 2 months 12 days	9 years 2 months 12 days
Non-employee options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 3.49
Expected term	9 years 3 months 18 days	9 years 10 months 24 days

Stock Options - Schedule of Res

Stock Options - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance	20,289
Unvested Number of Shares, Granted	65,450
Unvested Number of Shares, Vested	(4,057)
Unvested Number of Shares, Ending Balance	81,682
Weighted Average Fair Value per Share, Granted | $ / shares	$ 3.50
Weighted Average Fair Value per Share, Vested | $ / shares	$ 3.50

Stock Options - Schedule of RSU

Stock Options - Schedule of RSU Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Granted	787,500
Unvested Number of Shares, Vested	0
Unvested Number of Shares, Forfeited/cancelled	(68,500)
Unvested Number of Shares, Ending Balance	719,000
Weighted Average Fair Value per Share, Granted | $ / shares	$ 3.07
Weighted Average Fair Value per Share, Forfeited/cancelled | $ / shares	2.84
Weighted Average Fair Value per Share, Ending Balance | $ / shares	$ 3.10

Related Party Transactions - Sc

Related Party Transactions - Schedule of Amounts Due to Related Parties (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payable to related parties-current:
Total	$ 18	$ 55
Management services [Member]
Payable to related parties-current:
Management services provided by related parties	$ 18	$ 55

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Aug. 03, 2015	Feb. 28, 2015	Feb. 03, 2015	Jan. 14, 2015	Nov. 30, 2014	Feb. 06, 2014	Jul. 31, 2015	Jan. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions				$ 1,600,000	$ 23,500,000			$ 1,600,000		$ 1,559,000
Payment of bonus							$ 183,000
Due to related parties									$ 18,000	55,000
Orchard Capital Corporation [Member]
Related Party Transaction [Line Items]
General and administrative expense									14,000	139,000
Orchard Capital Corporation [Member] | Management and Accounting Services [Member]
Related Party Transaction [Line Items]
Due to related parties									4,000	2,000
C I M Group L P
Related Party Transaction [Line Items]
Due to related parties									14,000	53,000
Charges incurred									$ 73,000	$ 185,000
Presbia Holdings [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares	9,666,667					40,000
IPO [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares			4,166,667
IPO [Member] | Presbia Holdings [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares		500,000	500,000
2015 Capital Contribution [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares								9,166,667

Operating Segments and Geogra55

Operating Segments and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016CustomerSegment	Dec. 31, 2015Customer
Segment Reporting Revenue Reconciling Item [Line Items]
Number of reportable segments | Segment	1
Number of customers	3	6
Supplier agreement term	5 years
Sales [Member] | Customer Concentration [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk, percentage	100.00%	100.00%
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk, percentage	100.00%
Maximum [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Number of customers	1

Operating Segments and Geogra56

Operating Segments and Geographic Information - Schedule of Revenues Generated from External Customers and Long-lived Assets by Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 14	$ 153
Long Lived Assets	727	775
Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		2
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1	9
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	14	67
South Korea [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		44
The Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	(1)	29
UK [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		2
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	697	736
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	$ 30	$ 39

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Facility Leases [Member] - USD ($)	Aug. 01, 2016	Jan. 02, 2016	Dec. 01, 2013	May 31, 2012	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Rent expense						$ 388,000	$ 209,000
California [Member]
Commitments And Contingencies [Line Items]
Non-cancelable lease term				5 years
Lease expiration period	Sep. 30, 2020			May 31, 2017
Lease period	4 years
Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period			1 year
Lease renewal term						1 month
Lease commencement date						Jan. 1, 2016
The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period		30 months
Sub Lease Agreement [Member] | California [Member]
Commitments And Contingencies [Line Items]
Lease expiration period					Jul. 31, 2016
Lease period					26 months

Commitment and Contingencies -

Commitment and Contingencies - Annual Base Rental Cost Over the Term of the Leases (Detail) - Facility Leases [Member] $ in Thousands	Dec. 31, 2016USD ($)
Operating Leased Assets [Line Items]
2,017	$ 481
2,018	542
2,019	552
2,020	494
2,021	283
Thereafter	119
Total	$ 2,471

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Current provision:
Federal	$ 0	$ 0
State	4	3
Foreign	72	16
Total current	76	19
Deferred provision
Federal	(255)	(306)
State	0	0
Foreign	(1,228)	(1,574)
Total deferred	(1,483)	(1,880)
Valuation allowance	1,483	1,880
Total deferred	0	0
Total income tax provision	$ 76	$ 19

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Federal Statutory Rate to Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Expected income tax benefit at federal statutory rate	35.00%	35.00%
State tax provision, net of federal benefit	0.00%	0.00%
Foreign rate differential	(25.00%)	(25.00%)
Pass-through entities	(0.00%)	(0.00%)
Change in valuation allowance	(10.00%)	(10.00%)
Nondeductible expenses	0.00%	0.00%
Other	0.00%	0.00%
Income tax provision	0.00%	0.00%

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 4,444	$ 3,072
Accrued expenses	195	27
Stock based compensation	(11)	241
Deferred tax assets	4,628	3,340
Valuation allowance	(4,559)	(3,247)
Net deferred tax assets	69	93
Deferred tax liabilities:
Depreciation	(69)	(93)
Total deferred tax liabilities	$ (69)	$ (93)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Operating loss carryforwards	$ 2,000,000	$ 1,600,000
Operating loss carryforwards expiration year	2,033
Operating Loss Carryforwards, Limitations on Use	NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period
Unrecognized tax benefits	$ 0	0
Accrued interest and penalties	0	0
Ireland [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 30,000,000	$ 20,200,000

Subsequent Events - Additional

Subsequent Events - Additional information (Detail) $ / shares in Units, $ in Thousands	Feb. 06, 2017USD ($)SubscriptionRight$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Subsequent Events [Line Items]
Other issuance costs			$ 167	$ 2,431
Rights Offering [Member]
Subsequent Events [Line Items]
Net proceeds from issuance of ordinary shares		$ 10,500
Rights Offering [Member] | Subsequent Events [Member]
Subsequent Events [Line Items]
Subscription right received for each ordinary share owned | SubscriptionRight	1
Right to purchase ordinary shares | shares	0.335297256
Subscription price per share | $ / shares	$ 3
Number of ordinary shares, shares issued | shares	3,611,764
Gross proceeds from issuance of ordinary shares	$ 10,800
Other issuance costs	300
Net proceeds from issuance of ordinary shares	$ 10,500